Dimerix Limited · ASX:DXB
Dimerix — Investor Presentation (March 2022)
27 slides from Dimerix's investor presentation, Mar 29, 2022
Slide 1: Investor Presentation March 2022
@ Dimerix (ASX:DXB) Investor Presentation March 2022 Authorised for lodgment by the Board of the Company
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different fro
Slide 3: About Dimerix
About Dimerix Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on developing new therapies to treat inflammatory causes of kidney and respiratory disease FSGS Phase 3 clinical study opening across 12 countries globally! D
Slide 4: Share price and top shareholders
For personal use only Share price Top shareholders
Slide 5: Development pipeline
Development pipeline Program Indication Preclinical Phase 1 Phase 2 Phase 3 Key milestones . Phase 2a demonstrated encouraging efficacy & safety’; Phase 3 underway tac) Glomerular Sclerosis CF with regulatory &/or ethics authorisation in multiple countries?, 1* interim data anticipated H1 23? Diabet
Slide 6: DMX-200 — working on inflammatory signalling pathway
DMX-200 — working on inflammatory signalling pathway A CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR) XQ Small molecule Clear Development Path Easy and convenient dosing} Extensive regulatory new chemical entity status
Slide 7: DMX-200 proposed mechanism of action
DMX-200 proposed mechanism of action DMxX-200 addresses three key mechanisms that causes renal damage and sclerotic kidney disease . . DMX-200 inhibits chemokine receptor (CCR2) which initiates Irbesartan blocks angiotensin receptors (ATR) responsible attraction of inflammatory cells into the kidney
Slide 8: Kidney Disease Development Overview
Kidney Disease Development Overview
Slide 9: Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis * A rare disease that attacks part of the kidney, causing inflammation and irreversible scarring’; * Leads to permanent kidney damage and eventual end-stage kidney failure, requiring dialysis or transplantation Focal = some Segmental = sections Glomerulo = of the k
Slide 10: FSGS: unmet need and market potential
FSGS: unmet need and market | No therapies yet approved for FSGS otential "40,000 50% ~4000 aceni Die WSae of patients with FSGS | FSGS patients in US diagnosed with FSGS" will progress to kidney | receive a kidney failure? / transplant each year? ‘\ 2USS 7,008) () 20,000 2x Costicflaverage) feted a
Slide 11: FSGS Phase 3 study design
FSGS phase 3 study design nt ACTIAN3 A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes FSGS CLINICAL STUDY of DMX-200 in patients with primary FSGS receiving an ARB ARB stabilisation Treatment period weeks -6 -1 0 35 104 I il ! 6 oN 2 DMX-200 ® oI 2£f 2 2] = BI 3 a
Slide 12: For personal use only
For personal use only ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Slide 13: DMX-200 Intellectual property and exclusivity
DMX-200 Intellectual property and exclusivity /10 years 20414 2033 Orphan exclusivity in Method of Use Method of Use US/Europe2 Global application Granted? SN any CCR2 antagonist with any CCR2 inhibitor with any endothelin A receptor any ARB for any kidney for any disease disease Further application
Slide 14: Infection Related Pneumonia
Infection Related Pneumonia
Slide 15: Pneumonia (including COVID-19) market potential
Pneumonia (including COVID-19) market potential 3 million US$17 billion US$18.5 billion deaths annually caused pie COVID EREg mania market forecast responsible for US$17 by lower respiratory tract infections pre-COVID' expected by 2029, growing at 10%/year> billion in healthcare costs each year in t
Slide 16: Potential benefits of DMX-200
Potential benefits of DMX-200 Antiviral medications: Typically effective at preventing damage caused by a virus when administered days of infecti when many are asymptomatic 1. Brown L etal (2021) Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol
Slide 17: For personal use only
• • For personal use only • • • • • • • •
Slide 18: Additional longer term propositions
Additional longer term propositions
Slide 19: Additional asset value propositions
Additional asset value propositions Longer term opportunities Diversifying DMX-200 risk and Diabetic Kidney ferent Disease Uiee revenue Addressable market US$1.1 billion* Key driver is the rise in diabetes global incidence @ Dimerix 2017 IQVIA ARB prescription and pricing data; DMX-700 Chronic Obstr
Slide 20: For personal use only
For personal use only
Slide 21: For personal use only
For personal use only ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ❑ ❑ ❑ ❑ ❑ ❑
Slide 22: Dimerix
Dimerix A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. Advancing three Phase 3 opportunities Well positioned to deliver against strategic plan Dimerix HQ
Slide 23: Appendix
a@)\_ or personal use ‘= 7 _4 Dimerix, Appendix
Slide 24: Phase 2a DMX-200-202 (ACTION for FSGS) study
For personal use only Phase 2a DMX-200-202 (ACTION for FSGS): Phase 2a, Double-blind, Randomised, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of DMX-200 in Patients with Primary Focal Segmental Glomerulosclerosis who are Receiving Irbesartan • Primary endpoint: safety. Sec
Slide 25: DMX-200 inflammatory biomarker
DMX-200 inflammatory biomarker Average baseline MCP-1 versus average baseline proteinuria Dimerix Baseline uMCR (ng/mmol) 2 B =} S 1 Ny 8 L o o T T T 200 400 600 800 Baseline PCR (mg/mmol) 1 1000 DMX-200 Phase 2 study confirmed high MCP-1 correlates to high proteinuria in FSGS patients uMCR= Urinary
Slide 26: Change in PCR ratio DMX-200 vs placebo
Geometric mean difference -17% For personal use only (95% CI -43 to +20; p0.25) 0 Change in PCR ratio (%) -10 -20 -30 -40 -50 PPG Placebo DMX-200 • • ▪ ▪
Slide 27: DMX-200 treatment group met primary and secondary endpoints
DMX-200 treatment group met primary and secondary endpoints Average reduction in proteinuria after 16 weeks treatment on DMX-200 versus placebo compared [app erloleel-vanrelaringclecveMel|-t-lmlet-tal-liimicod oy-le(-1a M1 gers) to standard of care alone in FSGS patients! 0.0% 2 2 5.0% £8 as <y £3 S